avacopan (Tavneos)
Jump to navigation
Jump to search
Indications
- ANCA-associated vasculitis
- adjunctive therapy to cyclophosphamide or rituximab*
* non-inferior to prednisone as adjunctive therapy
Dosage
Adverse effects
- infections, including opportunistic infections*
- drug-induced liver injury including 7 cases of vanishing bile duct syndrome
- 8 death reported (as of 4/1/2026)
* prophylactic therapy for Pneumocystis jirovecii indicated
Mechanism of action
- C5a receptor (CD88) inhibitor
More general terms
References
- ↑ Jayne DRW, Merkel PA, Schall TJ, Bekker P for the ADVOCATE Study Avacopan for the Treatment of ANCA-Associated Vasculitis N Engl J Med 2021; 384:599-609. Feb 18 PMID: https://pubmed.ncbi.nlm.nih.gov/33596356 https://www.nejm.org/doi/full/10.1056/NEJMoa2023386
- ↑ AMA Morning Rounds. April 1, 2026 US FDA warns of liver injury linked to Amgen's avacopan, reports 8 deaths. American Medical Association
Singh P Reuters. March 31, 2020